Denileukin diftitox (brand name: Ontak, DAB389IL2) is the first recombinant immunotoxin approved by FDA for treatment of CTCL (cutaneous T cell lymphoma). This smart toxin is contains truncated diphtheria toxin (DT387), genetically fused to human interleukin 2 (IL2). Like other pharmaceutical productions, there is an aggregation problem in this fusion protein production and achieving a stable protein structure is mainly recommended for clinical use. Herein, we have investigated the effects of co-solvents on the structure and function of denileukin diftitox. In this work, the histidine-tagged DAB389IL2 was expressed in Escherichia coli and after solubilizing and refolding, the inclusion body was purified using nickel chelate affinity chromatography. Then, the structural alterations of the refolded protein in the presence of different co-solvents (sorbitol, trehalose, and sucrose) were investigated using fluorescence and circular dichroism (CD) techniques. Moreover, the nuclease activity of the refolded protein was traced to confirm the refolding process,. Finally, the biological activity of produced DAB389IL2 was carried out using MTT assay. The results revealed that, DAB389IL2 is more stable in PBS including sorbitol (30 mM) than other stabilizers. The tryptophan residues flexibility—exposure of DAB389IL2 to the solvent, in the presence of sorbitol, with respect to fluorescence quenching by acrylamide, indicated the best characterization. Also, in the presence of 2 ng/ml of protease, DAB389IL2 was completely undigested and so it indicated the highly stability of the fusion protein to proteases. Furthermore, the refolding and function of the produced fusion protein is verified by DNase activity and bioassay. Therefore, the data of this research could give further insights into the protein refolding mechanism and formulation of the protein in the presence of co-solvents.
Denileukin diftitox Immunotoxin Expression Stability Function
This is a preview of subscription content, log in to check access.
This study has been supported by the Malek-Ashtar University of Technology.
Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF (2001) Factors affecting short-term and long-term stabilities of proteins. Adv Drug Deliv Rev 46:307–326CrossRefGoogle Scholar
Chi EY, Krishnan S, Randolph TW, Carpenter JF (2003) Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20:1325–1336CrossRefGoogle Scholar
D’Amico S, Marx JC, Gerday C, Feller G (2003) Activity-stability relationships in extremophilic enzymes. J Biol Chem 278:7891–7896CrossRefGoogle Scholar
Duvic M, Talpur R (2008) Optimizing denileukin diftitox (ontak) therapy. Future Oncol 4:457–469CrossRefGoogle Scholar
Ebrahimi Bagha M, Zeinoddini M, Saeedinia AR, Xodadadi N (2018) Overexpression and purification of diphtheria fusion toxin: DAB389IL-2. J Bionanosci 12:688–693Google Scholar
Manoukian G, Hagemeister F (2009) Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 9:1445–1451CrossRefGoogle Scholar
Moghaddas M, Zeinoddini M, Saeedinia AR, Bayat S (2018) Structural and functional assessment of diphtheria fusion toxin: DT389GCSF. J Bionanosci 12(2):240–244CrossRefGoogle Scholar
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxcity assays. J Immunol Methods 65(1–2):55–63CrossRefGoogle Scholar
Murakami S, Kinoshita M (2016) Effects of monohydric alcohols and polyols on the thermal stability of a protein. J Chem Phys 144:125105CrossRefGoogle Scholar
Oshima H, Kinoshita M (2013) Effects of sugars on the thermal stability of a protein. J Chem Phys 138:245101CrossRefGoogle Scholar
Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559–565CrossRefGoogle Scholar
Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2007) Immunotoxin treatment of cancer. Annu Rev Med 58:221–237CrossRefGoogle Scholar
Sek DC (2008) Protein formulations containing sorbitol. US20080200655 A1Google Scholar
Shire SJ (2009) Formulation and manufacturability of biologics. Curr Opin Biotechnol 20:708–714CrossRefGoogle Scholar
Stevenson CL (2000) Characterization of protein and peptide stability and solubility in non-aqueous solvents. Curr Pharm Biotechnol 1:165–182CrossRefGoogle Scholar
Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, Duvic M (2006) CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 126:575–583CrossRefGoogle Scholar
Wang W (2005) Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289:1–3CrossRefGoogle Scholar
Weiss WF, Young TM, Roberts CJ (2009) Principles, approaches, and challenges for predicting aggregation rates and shelf life. J Pharm Sci 98(4):1246–1277CrossRefGoogle Scholar
Zeinoddini M, Khajeh K, Hosseinkhani S, Saeedinia AR, Robatjazi SM (2013) Stabilisation of recombinant aequorin by polyols: activity, thermostability and
limited proteolysis. Appl Biochem Biotechnol 170:273–280CrossRefGoogle Scholar